Didier Jutras-Aswad

Université de Montréal

Canada

Research Interests

Explore related searches

Professors in Canada

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (11)

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (7)

Rosalie Pacula

Professor

University of Southern California

UNITED STATES

View details

Wayne Hall

University of Queensland

AUSTRALIA

View details

Bernard Le Foll

University of Toronto

CANADA

View details

M. Eugenia Socias

University of British Columbia Faculty of Medicine

CANADA

View details

Philip Tibbo

Professor, Dr. Paul Janssen Chair in Psychotic Disorders

Dalhousie University Faculty of Medicine

CANADA

View details

David Whitehurst

Associate Professor

Simon Fraser University

CANADA

View details

Michel Perreault

CANADA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Didier Jutras-Aswad

Research Interests

Explore related searches

Contact this professor

Articles (11)

Impact of Depressive Symptom Severity on Buprenorphine/Naloxone and Methadone Outcomes in People With Prescription-Type Opioid Use Disorder: Results From a Pragmatic Randomized Controlled Trial

Las ‘Guías para el Uso de Cannabis de Menor Riesgo (GUCMR)’: RECOMENDACIONES [The ‘Lower-Risk Cannabis Use Guidelines (LRCUG)’: RECOMMENDATIONS (SPANISH)]

Les ‘Lignes Directrices Pour l'Usage du Cannabis à Moindre Risque (LUCMR)’: RECOMMENDATIONS [The ‘Lower-Risk Cannabis Use Guidelines (LRCUG)’: RECOMMENDATIONS (FRENCH)]

Recommendations for Reducing the Risk of Cannabis Use-Related Adverse Psychosis Outcomes: A Public Mental Health-Oriented Evidence Review

Risk-thresholds for the association between frequency of cannabis use and the development of psychosis: a systematic review and meta-analysis

Associations of methadone and buprenorphine‐naloxone doses with unregulated opioid use, treatment retention, and adverse events in prescription‐type opioid use disorders: Exploratory analyses of the OPTIMA study

Intravenous ketamine for benzodiazepine deprescription and withdrawal management in treatment-resistant depression: a preliminary report

Sensitivity to change of generic preference-based instruments (EQ-5D-3L, EQ-5D-5L, and HUI3) in the context of treatment for people with prescription-type opioid use disorder in Canada

Opioid agonist therapy switching among individuals with prescription-type opioid use disorder: Secondary analysis of a pragmatic randomized trial

People with opioid use disorders: A taxonomy of treatment entrants to support the development of a profile‐based approach to care

Cost-effectiveness of flexible take-home buprenorphine-naloxone versus methadone for treatment of prescription-type opioid use disorder

Collaborators (7)

Rosalie Pacula

Wayne Hall

Bernard Le Foll

M. Eugenia Socias

Philip Tibbo

David Whitehurst

Michel Perreault

Make your next move.